Infliximab

Home > Gastroenterology > Crohn's Disease > Infliximab

Infliximab is an advanced treatment option for Crohn's disease. It requires intravenous infusion and patients should respond within 14 weeks.

Pre-Treatment Tests

Test for tubeculosis and hepatitis B. Infliximab can cause reactivation of hepatitis B.

Treatment Regimens

Loading doses are 5 mg/kg at 0,2, and 6 weeks. Afterwards, the maintenance dose is 5 mg/kg every 8 weeks.

Please consider an official gastroenterology consult and refer to the sources below.

Gastroenterology